Welcome to our dedicated page for INmune Bio news (Ticker: INMB), a resource for investors and traders seeking the latest updates and insights on INmune Bio stock.
INmune Bio Inc. (NASDAQ: INMB) is a clinical-stage biotechnology company focused on developing novel immunotherapies that leverage the body’s innate immune system to fight cancer and other diseases. The company has a robust pipeline of product candidates, including INKmune™, INB03™, XPro™, and LIVNate™.
The company’s leading product, INKmune™, is designed to prime a patient’s natural killer (NK) cells to target and eliminate cancer cells that remain after initial treatment, thereby preventing relapse. By enhancing the functionality of NK cells, INKmune™ aims to boost the body’s ability to control residual disease, potentially extending patient survival.
INmune Bio’s INB03™ is a dominant-negative tumor necrosis factor (DN-TNF) inhibitor targeting high-risk breast cancers expressing MUC4 and triple-negative breast cancer (TNBC). Recent data presented at the American Association of Cancer Research in San Diego highlighted INB03™’s potential to decrease T cell and macrophage immune checkpoint proteins and reduce the metastatic potential of TNBC.
The company has also achieved significant milestones with XPro™, a treatment for Alzheimer’s Disease. INmune Bio recently announced the successful completion of the extended stability validation for continuous storage of XPro™ in solution, confirming its 24-month stability. The company is preparing for Phase III trials and commercial applications, leveraging established global distribution systems.
In addition, INmune Bio has entered into definitive agreements for the sale and purchase of nearly 1 million shares of its common stock and warrants, generating gross proceeds of approximately $9.7 million. These funds are earmarked to support ongoing clinical trials, including the Phase 2 trial for Alzheimer’s Disease and the Phase 1 trial for metastatic castration-resistant prostate cancer (mCRPC) using INKmune™.
The company’s management has focused on ensuring the safety and efficacy of their treatments. Recently, INKmune™ has shown promising results in initial clinical trials for mCRPC, with no significant adverse events reported, and approvals to proceed with further dosing cohorts.
For investors and stakeholders, INmune Bio provides a unique investment opportunity, combining cutting-edge science with a commitment to improving patient outcomes through innovative immunotherapy solutions. For more information, visit www.inmunebio.com.
INmune Bio (NASDAQ: INMB) has dosed its first patient in a Phase II trial for XPro1595, targeting mild Alzheimer’s disease. Financial results for Q1 2022 reveal a net loss of $6.9 million, up from $4.6 million the previous year, with revenues of $0.2 million. R&D expenses rose to $4.3 million, while cash reserves stood at $66.7 million as of March 31, 2022. Upcoming milestones include top-line results from pivotal trials expected in 2023, supporting the potential of their DN-TNF and INKmune platforms against various malignancies.
INmune Bio, Inc. (NASDAQ: INMB) is set to host a conference call and webcast on May 5, 2022, at 4:30 PM ET to discuss first-quarter results ending March 31, 2022, and provide a corporate update. The call can be accessed via dial-in numbers and a live audio webcast link. The company develops therapies targeting the innate immune system, with key products in clinical trials for conditions such as cancer and Alzheimer's disease. Investors are advised that outcomes of ongoing clinical trials remain uncertain as they await FDA approvals.
Boca Raton, FL, April 25, 2022 – INmune Bio (NASDAQ: INMB) announced participation in the B. Riley Neuro & Ophthalmology Conference on April 28, 2022. RJ Tesi, MD, President and CEO, will engage in a fireside chat at 11:00 am ET. This invitation-only event caters to B. Riley Securities' institutional clients. INmune Bio is focused on using the innate immune system to develop treatments for diseases such as cancer and Alzheimer's, with products like INB03™ and XPro™ in clinical trials.
INmune Bio (NASDAQ: INMB) has initiated patient enrollment for a crucial six-month Phase 2 trial assessing XPro1595 in patients with mild Alzheimer's disease (AD). This multicenter, randomized, placebo-controlled study aims to evaluate cognitive function and improvement in biomarkers associated with neuroinflammation. Following positive results from the Phase 1 trial, which showed a reduction in neuroinflammation and improvements in neurorepair biomarkers, the company anticipates enrolling 201 patients across the U.S., Australia, and Canada.
INmune Bio (NASDAQ: INMB) has announced significant findings regarding its product INB03 for treating trastuzumab-resistant MUC4 HER2+ breast cancer. Data from animal models indicate that INB03 effectively decreases MUC4 expression, reversing resistance to trastuzumab and tyrosine kinase inhibitors while enhancing an active tumor microenvironment. This research was presented at the American Association of Cancer Research Annual Meeting. Previous studies reveal MUC4 expression correlates with poorer survival outcomes. INB03 is poised for further clinical testing.
INmune Bio (NASDAQ: INMB) presented significant findings regarding its NK cell therapy, INKmune™, during the NK Cells in Solid Tumors workshop at the Innate Killer Summit. Dr. Mark Lowdell, the CSO, emphasized INKmune™'s unique ability to enhance NK cell survival and function in hostile tumor environments by upregulating mitochondrial proteins and nutrient receptors. Clinical data suggests that INKmune-primed NK cells can persist in the body for over 15 weeks, raising the potential for synergistic use with adoptive NK therapies. The company continues to explore collaborations for future clinical trials.
INmune Bio, Inc. (NASDAQ: INMB) announces that its Chief Scientific Officer, Dr. Lowdell, will lead a workshop at the 7th Innate Killer Summit in San Diego from March 30 to April 1, focusing on natural killer (NK) cells in treating solid tumors. The workshop aims to address challenges faced in NK cell therapies. Additionally, INmune will present case studies on INKmune™ showing promising results in three patients, including no side effects and improved disease outcomes. The company continues to advance its clinical trials targeting the innate immune system.
INmune Bio, Inc. (NASDAQ: INMB) recently presented at the AD/PD™ 2022 International Conference on Alzheimer's and Parkinson's diseases held from March 15-20 in Barcelona, Spain. The company emphasized the growing importance of targeting neuroinflammation in Alzheimer's Disease (AD) treatments, particularly with its Xpro™ therapy. Notable findings include improved synaptic function indicators post-treatment and the use of white matter pathology as a biomarker for predicting AD progression. CEO R.J. Tesi highlighted the significance of these insights in advancing clinical trials and drug development strategies.
INmune Bio (NASDAQ: INMB) presented nine data pieces at the AD/PD™ 2022 International Conference, held from March 15-20 in Barcelona, focusing on XPro™'s potential in treating Alzheimer’s Disease. This marks the first exposure for many EU and UK clinicians to INmune Bio’s approach targeting neuroinflammation. Key presentations include MRI measures from the Phase 1 trial and insights for Phase 2 trial design. The data emphasizes XPro™’s versatility and novel biomarkers being utilized in clinical strategies.
INmune Bio (NASDAQ: INMB), a clinical-stage immunology company, announced that its CEO, RJ Tesi, MD, will present at the 32nd Annual Oppenheimer Healthcare Conference from March 15-17, 2022. Dr. Tesi's corporate overview is scheduled for March 16, 2022, at 11:20am ET. Additionally, he will join a fireside chat at the 2022 Maxim Group Virtual Growth Conference on March 30, 2022, at 11:00am ET. INmune Bio is focused on treatments leveraging the immune system to combat diseases like cancer and Alzheimer's. Visit www.inmunebio.com for more information.
FAQ
What is the current stock price of INmune Bio (INMB)?
What is the market cap of INmune Bio (INMB)?
What is INmune Bio Inc.'s primary focus?
What is INKmune™?
What recent achievements has INmune Bio reported?
What is the significance of INB03™?
How does INmune Bio plan to use the recent funding?
What are the key components of INmune Bio’s product platforms?
What ongoing clinical trials are INmune Bio conducting?
How does INKmune™ work?
Is INmune Bio’s technology approved by the FDA?
How can investors get more information about INmune Bio?
